Analysis of Recurrent Angiotensin Converting Enzyme Inhibitor‐Induced Angioedema

Daniel S. Roberts,Elizabeth J. Mahoney,C. Hutchinson,Avner Aliphas,K. Grundfast
DOI: https://doi.org/10.1097/MLG.0b013e318182f805
IF: 2.97
2008-12-01
The Laryngoscope
Abstract:Objective/Hypothesis: A known risk for patients taking angiotensin converting enzyme‐inhibitors (ACE‐Is) is angioedema that can involve the face, lips, oral cavity, and larynx. Such upper airway obstruction may be severe enough to require an emergency department visit or even necessitate prompt airway intervention. Once a patient has had an episode of ACE‐inhibitor induced angioedema (AIIA), certainly a thrust of continuing case management would be to avoid the occurrence of subsequent episodes of AIIA that potentially can be life‐threatening. Nevertheless, recurrent episodes of AIIA do occur. This study aims to characterize a patient's risk for recurrent AIIA, determine the cause for repeat episodes of AIIA and recommend steps to be taken to minimize the recurrence of AIIA.
What problem does this paper attempt to address?